Aspirin: gastrointestinal risk may surpass cardiovascular benefits
The gastrointestinal ulcer risk taking aspirin may show greater cardiovascular benefits of this drug, warn researchers in a Spanish-American study published on the website of the journal "BMC Medicine."
Unlike other researchers who have conducted research on this topic, Sonia Hernandez-Diaz, an epidemiologist at Harvard University in Boston, and Luis Garcia Rodriguez, the pharmaco-epidemiological investigation Spanish center in Madrid, wanted to estimate the earnings report / risks of aspirin taking into account the initial risk of gastrointestinal and non cardiovascular risk patients.
For this, they analyzed two databases, one British, one Spanish, to determine the profile of patients taking low-dose aspirin in preventing a heart attack, in terms of factors major risk gastrointestinal they were likely to have.
Including these risk factors include advanced age, being a man of gastric ulcer history and non-steroidal anti-inflammatory drugs (NSAIDs). Among gastrointestinal complications include among other ulcer bleeding and perforation.
The researchers then estimated the excess gastrointestinal risk associated with the use of aspirin in the presence and in the absence of these risk factors.
Nearly nine out of ten consumers aspirin were more than sixty years, and 23% are men. Between 3.8 and 5.9% of them have a history of stomach ulcer.
In all risk groups, aspirin is responsible each year for five to six additional cases of upper gastrointestinal complications per 1,000 consumers. However, this excess risk is more important in populations at greater risk of gastrointestinal complications, such as older people or those with a history of gastric ulcer.
The authors estimate that the use of aspirin could be directly responsible each year for twenty additional cases of gastrointestinal complications 1,000 consumers in men over 70 years with a history of gastric ulcer.
Gastrointestinal damage aspirin could therefore exceed the cardiovascular benefits of this drug in people with high gastrointestinal risk and low cardiovascular risk, the authors conclude.
Unlike other researchers who have conducted research on this topic, Sonia Hernandez-Diaz, an epidemiologist at Harvard University in Boston, and Luis Garcia Rodriguez, the pharmaco-epidemiological investigation Spanish center in Madrid, wanted to estimate the earnings report / risks of aspirin taking into account the initial risk of gastrointestinal and non cardiovascular risk patients.
For this, they analyzed two databases, one British, one Spanish, to determine the profile of patients taking low-dose aspirin in preventing a heart attack, in terms of factors major risk gastrointestinal they were likely to have.
Including these risk factors include advanced age, being a man of gastric ulcer history and non-steroidal anti-inflammatory drugs (NSAIDs). Among gastrointestinal complications include among other ulcer bleeding and perforation.
The researchers then estimated the excess gastrointestinal risk associated with the use of aspirin in the presence and in the absence of these risk factors.
Nearly nine out of ten consumers aspirin were more than sixty years, and 23% are men. Between 3.8 and 5.9% of them have a history of stomach ulcer.
In all risk groups, aspirin is responsible each year for five to six additional cases of upper gastrointestinal complications per 1,000 consumers. However, this excess risk is more important in populations at greater risk of gastrointestinal complications, such as older people or those with a history of gastric ulcer.
The authors estimate that the use of aspirin could be directly responsible each year for twenty additional cases of gastrointestinal complications 1,000 consumers in men over 70 years with a history of gastric ulcer.
Gastrointestinal damage aspirin could therefore exceed the cardiovascular benefits of this drug in people with high gastrointestinal risk and low cardiovascular risk, the authors conclude.
SHARE THIS POST
